LinkedIn Icon Twitter Icon
Dates TBC (March 2019) | Boston, MA

Partnership Opportunities

Are you front of mind when biopharma companies look externally for assistance in the development of immuno-oncology therapeutics?

The sensational clinical and commercial success of checkpoint inhibitors is driving pharma and biotech to invest heavily in immune checkpoint inhibitor drug pipelines. With a wealth of late-stage programs and over 1000 clinical trials underway, the race to be the next to market is more competitive than ever

ICI Boston will bring together senior decision makers from drug developer organizations who are committed to optimizing the development of immuno-oncology therapeutics.

This meeting will offer you unrivalled opportunities to showcase your solutions, generate new business leads and source opportunities for partnerships.

Engage with the key people you need to, in order to stay ahead of the curve and secure your position in the IO space.

To find out more, email

Who you will meet:

Who You Will Meet

To find out more, email